Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R (1999) Increasing dose intensity of cisplatin–etoposide in advanced nonsmall cell lung ...

In patients with advanced nonsmall cell lung cancer resistant to EGFR inhibitors, adding a MET inhibitor to osimertinib was beneficial, but adding a MEK inhibitor was not.

June 2, 2009 (Orlando, Florida) — When combined with standard chemotherapy, a novel agent improves progression-free survival in patients with advanced nonsmall-cell lung cancer (NSCLC ...

KEY POINTSAcquired resistance to a specific inhibitor of an identified oncogenic mutation in advanced NSCLC is a clinical entity that is distinct from conventional management of ... Second-line ...

Background: Concurrent chemoradiotherapy is the standard of care for majority of medically fit locally advanced nonsmall cell carcinoma (IIIA, IIIB). The optimal chemotherapy regimen for use with ...

Results of the Phase 1-2 trial formed the basis of approval of selpercatinib in May 2020 by the US FDA for a) adults with metastatic RET-driven non-small cell lung cancer, b) adults and children ...

A prognostic and predictive biomarker for nonsmall cell lung cancer Date: June 1, 2010 Source: Publicase Comunicação Científica Summary: Researchers in Brazil found a protein that can be used ...

NEW YORK, June 11, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and ...